Pages that link to "Q44124410"
Jump to navigation
Jump to search
The following pages link to A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. (Q44124410):
Displaying 46 items.
- Is lipid signaling through cannabinoid 2 receptors part of a protective system? (Q24633122) (← links)
- Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background (Q26801046) (← links)
- Vascular targets for cannabinoids: animal and human studies (Q26862515) (← links)
- The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells (Q28236199) (← links)
- Role of platelets in neuroinflammation: a wide-angle perspective (Q28393808) (← links)
- Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation (Q30357558) (← links)
- Cannabinoids as novel anti-inflammatory drugs (Q33688381) (← links)
- Cannabinoids and Viral Infections. (Q33992923) (← links)
- The endocannabinoid system as a target for the treatment of neurodegenerative disease (Q34098196) (← links)
- A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. (Q34299290) (← links)
- A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats (Q34308648) (← links)
- Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists (Q34453695) (← links)
- Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. (Q34471868) (← links)
- Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis (Q34712554) (← links)
- HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. (Q34993393) (← links)
- Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS (Q35028750) (← links)
- Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors (Q35213727) (← links)
- A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis (Q35865445) (← links)
- Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions (Q35887816) (← links)
- Update on the role of cannabinoid receptors after ischemic stroke (Q35915645) (← links)
- PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis (Q36016406) (← links)
- The synthetic cannabinoid R( )WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α. (Q36127141) (← links)
- Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke (Q36247115) (← links)
- Modulating the endocannabinoid system in human health and disease--successes and failures (Q36933683) (← links)
- The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. (Q37568632) (← links)
- Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis (Q37628560) (← links)
- Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus. (Q37698703) (← links)
- Reduced immune cell infiltration and increased pro-inflammatory mediators in the brain of Type 2 diabetic mouse model infected with West Nile virus (Q37726328) (← links)
- Do cannabinoids have a therapeutic role in transplantation? (Q37768965) (← links)
- Neuroprotective agents: Cannabinoids (Q37855122) (← links)
- Cannabinoids, multiple sclerosis and neuroprotection (Q37960199) (← links)
- Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation (Q38087533) (← links)
- Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier (Q38220272) (← links)
- Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses. (Q38324480) (← links)
- Animal models of Multiple Sclerosis. (Q38396248) (← links)
- Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors (Q38572902) (← links)
- An update on PPAR activation by cannabinoids. (Q38808034) (← links)
- Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial (Q39200153) (← links)
- The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets (Q41821312) (← links)
- Cannabinoid receptor-2 and HIV-associated neurocognitive disorders. (Q42206762) (← links)
- 2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. (Q52372355) (← links)
- Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. (Q52678835) (← links)
- Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis (Q58720580) (← links)
- Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis. (Q64986099) (← links)
- Cannabinoid Receptor and N‐acyl Phosphatidylethanolamine Phospholipase D—Evidence for Altered Expression in Multiple Sclerosis (Q83248279) (← links)
- Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review (Q90092927) (← links)